The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

267 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For type-1 diabetes, the aim of insulin therapy is to keep blood glucose close to normal while avoiding hypoglycaemia but this is severely limited by the relative crudeness of current insulin delivery in comparison with the physiology of the β-cells which secrete insulin. Insulin is generally administered by multiple injections MDI with the dose adjusted according to eating and exercise. Insulin can now also be administered using a pump (CSII), which is a device, roughly the size of a mobile phone and containing sufficient insulin to supply both the needs of basal metabolism throughout the day, and the boluses which have to cover meals. The use of CSII is expensive compared to injections, but there are important potential benefits which include improved glycaemic control, reduced risk of hypoglycaemia (low blood sugar) and a more flexible lifestyle and better quality of life. There have been no trials in adults that have compared CSII treatment with MDI where the same structured training in intensive insulin therapy has been given, so the precise benefit of the pump technology is still unclear. There is a need to establish this, and identify patients who benefit the most so that the Department of Health can calculate the proportion of adults that would benefit from CSII therapy and so ensure that commissioning bodies provide the necessary reimbursement. The aim of the trial is therefore to establish the added benefit of CSII therapy over multiple injections on glycaemic control and hypoglycaemia in individuals with Type 1 diabetes receiving similar high quality structured training (Dose Adjustment For Normal Eating:DAFNE) in insulin therapy. Additional assessments will include effects on quality of life and cost effectiveness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

NCT02081001

Hypoglycemia

COMPLETED PHASE2

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

NCT03490942

Hypoglycemia Unawareness Diabetes Mellitus, Type 1

TERMINATED PHASE2

Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion

NCT01557907

Diabetes

COMPLETED PHASE1/PHASE2

Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin

NCT05768191

Type 1 Diabetes

COMPLETED PHASE4

Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System

NCT03478969

Diabetes Mellitus, Type 1

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is a multi-centre randomised controlled trial whereby between 40 and 49 type-1 diabetic, adult volunteers, aged 18 and above, will be recruited per site from 7 secondary care centres (Sheffield, Kings College Hospital London, Harrogate District Hospital, Addenbrookes Hospital Cambridge, Glasgow Royal Infirmary, Dumfries and Galloway Royal Infirmary and Edinburgh Royal Infirmary). The sites will be required to recruit participants to at least 3 CSII DAFNE (Dose Adjustment for Normal Eating)courses and 3 MDI DAFNE courses. This will mean that in total on the trial, 140 participants are randomised to CSII and 140 to MDI. Participants will be recruited through direct approach if already on the waiting list for a DAFNE course or through advertisement in various clinics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple daily injections plus DAFNE

Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues

Group Type ACTIVE_COMPARATOR

MDI (levemir® & quick acting insulin) plus DAFNE

Intervention Type OTHER

Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues

CSII (Insulin Pump) plus DAFNE

Medtronic MiniMed Paradigm Veo Insulin pumps (X54)

Group Type EXPERIMENTAL

CSII (Insulin Pump) plus DAFNE

Intervention Type OTHER

Medtronic MiniMed Paradigm Veo Insulin pumps (X54)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CSII (Insulin Pump) plus DAFNE

Medtronic MiniMed Paradigm Veo Insulin pumps (X54)

Intervention Type OTHER

MDI (levemir® & quick acting insulin) plus DAFNE

Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Continuous subcutaneous insulin infusion CSII external insulin pumps

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is aged 18 yrs and above.
* Have had type-1 diabetes for at least 12 months (as assessed by date clinically diagnosed).
* Is fluent in speaking, reading and understanding English.
* Has no preference to either CSII or MDI arm of the study and is happy to be randomised.
* Is currently using or willing to switch to Detemir.
* Is willing to undertake self-monitoring of blood glucose (SMBG), carbohydrate counting and insulin self-adjustment. (Enrolment staff should check that any participant with a baseline HbA1c of above 12% is willing to complete SMBG).
* Has a need for structured education to optimise diabetes control in the opinion of the investigator.

Exclusion Criteria

* Inability to give informed consent.
* Is pregnant or planning to become pregnant within the next 2 years.
* Has used CSII within the last 3 years.
* Has already completed a diabetes education course.
* Has severe needle phobia.
* Has a current history of alcohol or drug abuse.
* Has a history of heart disease within the past 3 months.
* Has hypertension that is not under control with hypertensive medication (diastolic blood pressure \>100mmHg and or sustained systolic level \>160).
* Has renal impairment with a chance of needing renal replacement therapy within the next 2 years (Enrolment staff should check that creatinine levels are not above 200 µmol/L).
* Has recurrent episodes of skin infections.
* Has serious or unstable medical or psychological conditions.
* Has taken part in any other investigational clinical trial during the 4 months prior to screening.
* Has any other issue that may preclude the participant from satisfactory participation in the study based on investigatory judgement.
* Has a strong need for pump therapy in the opinion of the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Simon Heller, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Sheffield

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Addenbrookes Wolfson Diabetes and Endocrine Clinic, Box 281, Addenbrookes Hospital, Hills Road

Cambridge, Cambridgeshire, United Kingdom

Site Status

Harrogate District Hospital, Diabetes Centre, Lancaster Park Road,

Harrogate, North Yorkshire, United Kingdom

Site Status

Dumfries and Galloway Royal Infirmary, Diabetes Centre, Cluden West, Crichton Hall,

Dumfries, Scotland, United Kingdom

Site Status

Royal Infirmary of Edinburgh, Department of Diabetes, 51 Little France Crescent

Edinburgh, Scotland, United Kingdom

Site Status

Stobhill ACH, Diabetes Clinic, 133 Balornock Road

Glasgow, Scotland, United Kingdom

Site Status

Sheffield Teaching Hospital, Diabetes Centre, Northern General Hospital, PO Box 1, Herries Road

Sheffield, South Yorkshire, United Kingdom

Site Status

Kings College Hospital, Diabetes Centre, Suite 3, Golden Jubilee Wing, Denmark Hill

London, , United Kingdom

Site Status

Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus, Derby Road

Nottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017 Mar 30;356:j1285. doi: 10.1136/bmj.j1285.

Reference Type RESULT

PMID: 28360027 (View on PubMed)

Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, Amiel S, Barnard K, Beckwith A, Brennan A, Campbell M, Cooper C, Dimairo M, Dixon S, Elliott J, Evans M, Green F, Hackney G, Hammond P, Hallowell N, Jaap A, Kennon B, Kirkham J, Lindsay R, Mansell P, Papaioannou D, Rankin D, Royle P, Smithson WH, Taylor C. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess. 2017 Apr;21(20):1-278. doi: 10.3310/hta21200.

Reference Type RESULT

PMID: 28440211 (View on PubMed)

Bradburn MJ, Lee EC, White DA, Hind D, Waugh NR, Cooke DD, Hopkins D, Mansell P, Heller SR. Treatment effects may remain the same even when trial participants differed from the target population. J Clin Epidemiol. 2020 Aug;124:126-138. doi: 10.1016/j.jclinepi.2020.05.001. Epub 2020 May 11.

Reference Type DERIVED

PMID: 32438024 (View on PubMed)